On June 4, 2025, Scindy Pharmaceutical (Suzhou) Co., Ltd. (hereinafter referred to as "Scindy Pharmaceutical") and Guangzhou GENESEED Biotechnology Co., Ltd. (hereinafter referred to as "GENESEED Bio") officially signed a strategic cooperation agreement today. Based on their respective deep accumulations in lipid nanoparticle (LNP) delivery technology and circRNA in vitro synthesis stock solution field, the two parties will achieve complementary advantages and resource sharing, jointly promote the development of circRNA-LNP therapy, the adaptability verification of delivery systems, and the application of long-acting expression technology, and significantly enhance their comprehensive competitiveness in the field of circular RNA drug research and development.
Chen Xiaobao, Founder/CEO of Scindy Pharmaceutical (left), Liu Ming, Founder/CEO of GENESEED Biotechnology (right)
Scindy Pharmaceutical and Jisai Biotechnology highly recognize each other's strategic value and regard this cooperation as an important milestone. Both parties will rely on the deep integration of the two core technologies of "circRNA design and preparation" and "LNP delivery system" to build an innovative model that breaks through technological barriers and jointly builds an industrial ecosystem. By integrating technological and industrial advantages, both parties are committed to achieving full chain collaboration from cutting-edge technology research and development to clinical applications, creating a one-stop solution covering sequence optimization, in vitro synthesis, and targeted delivery for global customers, accelerating the research and industrialization process of innovative circular RNA therapies.
Chen Xiaobao, founder/CEO of Scindy Pharmaceutical, said:
GENESEED Biotechnology is a pioneer in the scientific research and application transformation of circular RNA, and has established a leading system for screening, sequence design, process development, and raw material preparation of circular RNA drugs. Scindy Pharmaceutical has underlying technological advantages and rich product development experience in the field of LNP carriers. This cooperation will effectively promote the deep integration of 'circRNA+LNP' technology, leverage strong synergies, significantly improve the efficiency and quality of drug development, and make important contributions to the research and industrialization of circRNA drugs in China and even globally.
Liu Ming, founder/CEO of GENESEED Biotechnology, stated:
Circular RNA is regarded by the industry as the preferred RNA platform for next-generation vaccines and drugs, and an efficient delivery system is a key factor in its in vivo function. Shengdi Biotechnology has outstanding technological advantages in the field of LNP. We are very pleased to establish a strategic cooperation with Scindy Pharmaceutical, fully integrating the advantages of both parties' resources, and jointly promoting the development of circRNA LNP therapy to provide more outstanding solutions for global customers
Regarding Partners
-
Scindy Pharmaceutical: Focusing on independent innovation of nanocarrier technology as the core, promoting innovative research and clinical translation of RNA therapy and other synthetic biology technologies. The company has established a full chain LNP delivery technology solution (TLS) driven by artificial intelligence and rational empirical evidence, with a core lipid material library NeoLNP ™ A series of reagent kits (stem cell/immune cell/animal in vivo RNA transfection) and RNA sequence design models have been developed, and i-Core LNP represented by lung nebulization inhalation and skin local administration has been successfully developed ™ Extrahepatic targeted RNA delivery protocol.
-
GENESEED Biotechnology: As a pioneer in the field of circular RNA, GENESEED Biotechnology has overcome the key technological bottleneck of circular RNA drug development and independently developed various strategies for circular RNA drug formation. Relying on strong original research capabilities, the company has established multiple technology platforms covering gene synthesis, raw material synthesis, high-throughput sequencing, bioinformatics analysis, etc., providing one-stop circular RNA drug development CRO solutions from drug screening, sequence design, process development, large-scale production to efficacy evaluation, committed to empowering global drug research and development partners.
Looking Forward
This strategic cooperation marks a solid step forward for the two companies in the field of circular RNA therapy. Both parties will work together to overcome technical difficulties, accelerate the development of innovative therapies, and jointly shape a new pattern of RNA drug research and development.
